Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383756 | 0.83 | — | — | |
| SCHEMBL1362168 | 0.83 | — | — | |
| SCHEMBL383884 | 0.83 | — | — | |
| SCHEMBL387198 | 0.79 | ALDH1A1 (0.37) | ALDH1A1MEN1RAB9AKMT2AKCNH2 | |
| SCHEMBL386306 | 0.78 | CXCR2 (0.38) | ALDH1A1KDM4EGRM5POLBMAPT | |
| SCHEMBL386545 | 0.76 | KCNH2 (0.39) | ALDH1A1MEN1RAB9AKMT2AKCNH2 | |
| SCHEMBL384086 | 0.76 | KCNH2 (0.39) | ALDH1A1MEN1RAB9AKMT2AKCNH2 | |
| Oxalic Acid SCHEMBL387197 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MEN1RAB9AKMT2AKCNH2 | |
| SCHEMBL386235 | 0.75 | — | — | |
| SCHEMBL386064 | 0.74 | S1PR1 (0.46) | ALDH1A1MEN1RAB9AKMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20090326038-A1 | Method for treating a immunology-related disease | SANKYO COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7638551-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| EP-1471054-B1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070105933-A1 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7199150-B2 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | SANKYO COMPANY, LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | PHOSPHO1, CD4, FCGRT | ALDH1A1 945/4885MEN1 1065/4885RAB9A 1886/4885 |
| US-20090326038-A1 | Method for treating a immunology-related disease | C3AR1, HRH3, HRH2 | ALDH1A1 2821/4885MEN1 307/4885RAB9A 2460/4885 |
| US-20070105933-A1 | Amino alcohol compounds | ADH1C, C9, SSB | ALDH1A1 582/4885MEN1 1067/4885RAB9A 2503/4885 |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | HRH3, C3AR1, HRH4 | ALDH1A1 1443/4885MEN1 1225/4885RAB9A 1873/4885 |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | PHOSPHO1, ADH1C, ADH1A | ALDH1A1 898/4885MEN1 940/4885RAB9A 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.